Keratoconjunctivitis sicca (Dry Eye) - Pipeline Review, H2 2016

Publisher Name :
Date: 14-Sep-2016
No. of pages: 192
Inquire Before Buying

Global Markets Direct's, ‘Keratoconjunctivitis sicca (Dry Eye) - Pipeline Review, H2 2016', provides an overview of the Keratoconjunctivitis sicca (Dry Eye) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Keratoconjunctivitis sicca (Dry Eye), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Keratoconjunctivitis sicca (Dry Eye) and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Keratoconjunctivitis sicca (Dry Eye)

  • The report reviews pipeline therapeutics for Keratoconjunctivitis sicca (Dry Eye) by companies and universities/research institutes based on information derived from company and industry-specific sources

  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

  • The report reviews key players involved Keratoconjunctivitis sicca (Dry Eye) therapeutics and enlists all their major and minor projects

  • The report assesses Keratoconjunctivitis sicca (Dry Eye) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

  • The report summarizes all the dormant and discontinued pipeline projects

  • The report reviews latest news related to pipeline therapeutics for Keratoconjunctivitis sicca (Dry Eye)

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

  • Identify and understand important and diverse types of therapeutics under development for Keratoconjunctivitis sicca (Dry Eye)

  • Identify potential new clients or partners in the target demographic

  • Develop strategic initiatives by understanding the focus areas of leading companies

  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

  • Devise corrective measures for pipeline projects by understanding Keratoconjunctivitis sicca (Dry Eye) pipeline depth and focus of Indication therapeutics

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Keratoconjunctivitis sicca (Dry Eye) - Pipeline Review, H2 2016

Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Keratoconjunctivitis sicca (Dry Eye) Overview 9
Therapeutics Development 10
Pipeline Products for Keratoconjunctivitis sicca (Dry Eye) - Overview 10
Pipeline Products for Keratoconjunctivitis sicca (Dry Eye) - Comparative Analysis 11
Keratoconjunctivitis sicca (Dry Eye) - Therapeutics under Development by Companies 12
Keratoconjunctivitis sicca (Dry Eye) - Therapeutics under Investigation by Universities/Institutes 16
Keratoconjunctivitis sicca (Dry Eye) - Pipeline Products Glance 17
Late Stage Products 17
Clinical Stage Products 18
Early Stage Products 19
Unknown Stage Products 20
Keratoconjunctivitis sicca (Dry Eye) - Products under Development by Companies 21
Keratoconjunctivitis sicca (Dry Eye) - Products under Investigation by Universities/Institutes 25
Keratoconjunctivitis sicca (Dry Eye) - Companies Involved in Therapeutics Development 26
AB2 Bio Ltd. 26
Allergan Plc 27
Ascendia Pharmaceuticals LLC 28
Chong Kun Dang Pharmaceutical Corp. 29
Digna Biotech, S.L. 30
Dompe Farmaceutici S.p.A. 31
HanAll Biopharma Co., Ltd. 32
Herantis Pharma Plc 33
Huons Co., Ltd. 34
InSite Vision Incorporated 35
Kala Pharmaceuticals, Inc. 36
Kissei Pharmaceutical Co., Ltd. 37
KPI Therapeutics, Inc. 38
Kukje Pharmaceutical Industry Co., Ltd. 39
Laboratoires Thea S.A. 40
Lee's Pharmaceutical Holdings Limited 41
Lipicard Technologies Limited 42
Merck & Co., Inc. 43
Mimetogen Pharmaceuticals Inc. 44
Mitotech S.A. 45
Nanomerics Ltd 46
Neuroptis Biotech 47
Novaliq GmbH 48
Ocular Therapeutix, Inc. 49
Oculis ehf 50
OncoNOx ApS 51
Otsuka Holdings Co., Ltd. 52
Parion Sciences, Inc. 53
Quorum Innovations LLC 54
RegeneRx Biopharmaceuticals, Inc. 55
Rigel Pharmaceuticals, Inc. 56
Samjin Pharmaceutical Co., Ltd. 57
Santen Pharmaceutical Co., Ltd. 58
Seikagaku Corporation 59
Sucampo Pharmaceuticals, Inc. 60
TearSolutions, LLC. 61
TopiVert Ltd 62
Xigen SA 63
Keratoconjunctivitis sicca (Dry Eye) - Therapeutics Assessment 64
Assessment by Monotherapy Products 64
Assessment by Target 65
Assessment by Mechanism of Action 69
Assessment by Route of Administration 73
Assessment by Molecule Type 75
Drug Profiles 77
AGN-223575 - Drug Profile 77
AGN-232411 - Drug Profile 78
Androgen Tears - Drug Profile 79
AVA-3486 - Drug Profile 80
AVX-012 - Drug Profile 81
BRM-421 - Drug Profile 82
cinhyaluronate sodium - Drug Profile 83
Cis-Urocanic Acid - Drug Profile 84
cyclosporine - Drug Profile 87
cyclosporine - Drug Profile 90
cyclosporine - Drug Profile 92
cyclosporine - Drug Profile 93
cyclosporine - Drug Profile 94
cyclosporine - Drug Profile 95
cyclosporine - Drug Profile 96
cyclosporine - Drug Profile 97
cyclosporine SR - Drug Profile 98
dexamethasone acetate SR - Drug Profile 99
diclofenac sodium - Drug Profile 104
diquafosol tetrasodium - Drug Profile 105
disitertide - Drug Profile 107
Drugs to Agonize FPR2 for Dry Eye - Drug Profile 109
Elate Ocular - Drug Profile 110
HL-036 - Drug Profile 111
HU-007 - Drug Profile 112
hyaluronate sodium - Drug Profile 113
ISV-101 - Drug Profile 114
K-089 - Drug Profile 115
KeraKlear - Drug Profile 116
KJ-14003 - Drug Profile 117
KL-7016 - Drug Profile 118
KPI-190 - Drug Profile 119
Lacripep - Drug Profile 120
LME-636 - Drug Profile 121
loteprednol etabonate - Drug Profile 122
LT-4002 - Drug Profile 125
LT-4003 - Drug Profile 126
NOP-3 - Drug Profile 127
NOP-5 - Drug Profile 128
Nov-03 - Drug Profile 129
OC-301 - Drug Profile 130
OX-1001 - Drug Profile 131
ozagrel - Drug Profile 132
P-321 - Drug Profile 133
plastoquinone decyl triphenylphosphonium bromide - Drug Profile 135
PPL-003 - Drug Profile 137
Qi-204 - Drug Profile 139
R-348 - Drug Profile 140
rebamipide - Drug Profile 142
Recombinant Protein to Agonize p75NTR and Trk for Ophthalmology - Drug Profile 144
RGN-259 - Drug Profile 146
RP-101 - Drug Profile 153
RU-101 - Drug Profile 154
SA-001 - Drug Profile 156
SJP-002 - Drug Profile 157
Small Molecule to Agonize Glucocorticoid Receptor for Dry Eye - Drug Profile 158
ST-266 - Drug Profile 159
tadekinig alfa - Drug Profile 161
tavilermide hydrochloride - Drug Profile 162
TOP-1630 - Drug Profile 164
XG-104 - Drug Profile 165
ZK-003 - Drug Profile 166
zucapsaicin - Drug Profile 167
Keratoconjunctivitis sicca (Dry Eye) - Dormant Projects 169
Keratoconjunctivitis sicca (Dry Eye) - Discontinued Products 175
Keratoconjunctivitis sicca (Dry Eye) - Product Development Milestones 176
Featured News & Press Releases 176
Appendix 187
Methodology 187
Coverage 187
Secondary Research 187
Primary Research 187
Expert Panel Validation 187
Contact Us 187
Disclaimer 188

List of Tables

Number of Products under Development for Keratoconjunctivitis sicca (Dry Eye), H2 2016 14
Number of Products under Development for Keratoconjunctivitis sicca (Dry Eye) - Comparative Analysis, H2 2016 15
Number of Products under Development by Companies, H2 2016 17
Number of Products under Development by Companies, H2 2016 (Contd..1) 18
Number of Products under Development by Companies, H2 2016 (Contd..2) 19
Number of Products under Investigation by Universities/Institutes, H2 2016 20
Comparative Analysis by Late Stage Development, H2 2016 21
Comparative Analysis by Clinical Stage Development, H2 2016 22
Comparative Analysis by Early Stage Development, H2 2016 23
Comparative Analysis by Unknown Stage Development, H2 2016 24
Products under Development by Companies, H2 2016 25
Products under Development by Companies, H2 2016 (Contd..1) 26
Products under Development by Companies, H2 2016 (Contd..2) 27
Products under Development by Companies, H2 2016 (Contd..3) 28
Products under Investigation by Universities/Institutes, H2 2016 29
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by AB2 Bio Ltd., H2 2016 30
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Allergan Plc, H2 2016 31
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Ascendia Pharmaceuticals LLC, H2 2016 32
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Chong Kun Dang Pharmaceutical Corp., H2 2016 33
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Digna Biotech, S.L., H2 2016 34
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Dompe Farmaceutici S.p.A., H2 2016 35
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by HanAll Biopharma Co., Ltd., H2 2016 36
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Herantis Pharma Plc, H2 2016 37
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Huons Co., Ltd., H2 2016 38
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by InSite Vision Incorporated, H2 2016 39
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Kala Pharmaceuticals, Inc., H2 2016 40
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Kissei Pharmaceutical Co., Ltd., H2 2016 41
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by KPI Therapeutics, Inc., H2 2016 42
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Kukje Pharmaceutical Industry Co., Ltd., H2 2016 43
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Laboratoires Thea S.A., H2 2016 44
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Lee's Pharmaceutical Holdings Limited, H2 2016 45
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Lipicard Technologies Limited, H2 2016 46
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Merck & Co., Inc., H2 2016 47
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Mimetogen Pharmaceuticals Inc., H2 2016 48
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Mitotech S.A., H2 2016 49
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Nanomerics Ltd, H2 2016 50
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Neuroptis Biotech, H2 2016 51
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Novaliq GmbH, H2 2016 52
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Ocular Therapeutix, Inc., H2 2016 53
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Oculis ehf, H2 2016 54
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by OncoNOx ApS, H2 2016 55
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Otsuka Holdings Co., Ltd., H2 2016 56
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Parion Sciences, Inc., H2 2016 57
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Quorum Innovations LLC, H2 2016 58
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by RegeneRx Biopharmaceuticals, Inc., H2 2016 59
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Rigel Pharmaceuticals, Inc., H2 2016 60
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Samjin Pharmaceutical Co., Ltd., H2 2016 61
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Santen Pharmaceutical Co., Ltd., H2 2016 62
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Seikagaku Corporation, H2 2016 63
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Sucampo Pharmaceuticals, Inc., H2 2016 64
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by TearSolutions, LLC., H2 2016 65
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by TopiVert Ltd, H2 2016 66
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Xigen SA, H2 2016 67
Assessment by Monotherapy Products, H2 2016 68
Number of Products by Stage and Target, H2 2016 70
Number of Products by Stage and Mechanism of Action, H2 2016 74
Number of Products by Stage and Route of Administration, H2 2016 78
Number of Products by Stage and Molecule Type, H2 2016 80
Keratoconjunctivitis sicca (Dry Eye) - Dormant Projects, H2 2016 173
Keratoconjunctivitis sicca (Dry Eye) - Dormant Projects (Contd..1), H2 2016 174
Keratoconjunctivitis sicca (Dry Eye) - Dormant Projects (Contd..2), H2 2016 175
Keratoconjunctivitis sicca (Dry Eye) - Dormant Projects (Contd..3), H2 2016 176
Keratoconjunctivitis sicca (Dry Eye) - Dormant Projects (Contd..4), H2 2016 177
Keratoconjunctivitis sicca (Dry Eye) - Dormant Projects (Contd..5), H2 2016 178
Keratoconjunctivitis sicca (Dry Eye) - Discontinued Products, H2 2016 179

List of Figures

Number of Products under Development for Keratoconjunctivitis sicca (Dry Eye), H2 2016 14
Number of Products under Development for Keratoconjunctivitis sicca (Dry Eye) - Comparative Analysis, H2 2016 15
Number of Products under Development by Companies, H2 2016 16
Comparative Analysis by Late Stage Development, H2 2016 21
Comparative Analysis by Clinical Stage Development, H2 2016 22
Comparative Analysis by Early Stage Products, H2 2016 23
Assessment by Monotherapy Products, H2 2016 68
Number of Products by Top 10 Targets, H2 2016 69
Number of Products by Stage and Top 10 Targets, H2 2016 69
Number of Products by Top 10 Mechanism of Actions, H2 2016 73
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 73
Number of Products by Top 10 Routes of Administration, H2 2016 77
Number of Products by Stage and Top 10 Routes of Administration, H2 2016 77
Number of Products by Molecule Types, H2 2016 79
Number of Products by Stage and Molecule Types, H2 2016 79
  • Manufacturing Trends In The Coming Days
    The manufacturing industry may be encountering some breezes, but it is irrefutably in the middle of a technological revival that is altering the appearance, structures, and practices of the modern factory. Notwithstanding the jeopardies and in spite of recent history industrial manufacturing enterprises cannot afford to disregard these developments. Few of the trends to look […]
  • Top 10 Emerging Technologies
    The World Economic Forum (WEF) and Scientific American lately unveiled the major technological innovation list of the top ten emerging technologies. This list emphasizes on the technological developments which have the supremacy to transform industries, protect the planet, and improve lives. It also presents an opening to discuss any societal, human, economic or environmental jeopardies […]
  • Global Biosimilars Market To Be Led By Novartis by 2020
    Biologics, which are typically inoculated or injected, are formed in living entities, making them more challenging and costly to manufacture than the usual pills contrived from chemicals. Observing that mock-ups are mostly identical to the prototypes has also modelled specific scientific and regulatory tasks. But the US FDA and European supervisors lately have acknowledged new […]
  • Global Thyroid Gland Disorder Treatment Market To Grow Steadily
    The global thyroid gland disorder treatment market was worth US$1.8 billion in 2014 and is projected to reach a market value of US$2.4 billion in 2023 intensifying at a CAGR of 3.1% from 2015 to 2023.  The thyroid gland produces thyroid hormones that control some of the most essential functions in the human body such as stimulating […]
  • Asia Pacific Makeup Market To Grow Owing To Impactful Promotion And Progress Of Distribution Networks
    The Asia Pacific makeup market is one of the most assorted and active markets in the cosmetics industry throughout the world and is projected to grow at a CAGR of 7.1% between 2013 and 2019. The makeup market in Asia Pacific is assessed to be worth US$22.31 billion by 2019. The world-wide market was at an approximation of US$14.76 […]
  • Global (North America, Europe and Asia-Pacific, South America, Middle East and Africa) Eye Drops & Lubricants Market 2017 Forecast to 2022
    Published: 10-Apr-2017        Price: US 4880 Onwards        Pages: 117
    Eye drops are saline-containing drops used as an ocular route to administer. Depending on the condition being treated, they may contain steroids, antihistamines, sympathomimetics, beta receptor blockers, parasympathomimetics, parasympatholytics, prostaglandins, nonsteroidal anti-inflammatory drugs (NSAIDs), antibiotics, antifungal, or topical anesthetics. Eye drops sometimes do not have medications in them and are only lubricating and tear-replacing solutions.Scope of the Report:......
  • Global Eye Drops & Lubricants Market by Manufacturers, Countries, Type and Application, Forecast to 2022
    Published: 07-Apr-2017        Price: US 3480 Onwards        Pages: 117
    Eye drops are saline-containing drops used as an ocular route to administer. Depending on the condition being treated, they may contain steroids, antihistamines, sympathomimetics, beta receptor blockers, parasympathomimetics, parasympatholytics, prostaglandins, nonsteroidal anti-inflammatory drugs (NSAIDs), antibiotics, antifungal, or topical anesthetics. Eye drops sometimes do not have medications in them and are only lubricating and tear-replacing solutions.Scope of the Report:......
  • United States Glaucoma Therapeutics Market Report 2017
    Published: 03-Apr-2017        Price: US 3800 Onwards        Pages: 98
    In this report, the United States Glaucoma Therapeutics market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report splits the United States market into seven regions: - The West - Southwest - The Middle Atlantic - New England - The South - The Midwest with sales (volume), revenue (value), market share and growth ra......
  • Viral Conjunctivitis - Pipeline Review, H1 2017
    Published: 31-Mar-2017        Price: US 2000 Onwards        Pages: 43
    Viral Conjunctivitis - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Viral Conjunctivitis - Pipeline Review, H1 2017, provides an overview of the Viral Conjunctivitis (Ophthalmology) pipeline landscape. Viral conjunctivitis, or pinkeye, is a common, self-limiting condition that is typically caused by adenovirus. Viral conjunctivitis is highly contagious, usually for 10-12 days from o......
  • Blepharitis - Pipeline Review, H1 2017
    Published: 31-Mar-2017        Price: US 2000 Onwards        Pages: 54
    Blepharitis - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Blepharitis - Pipeline Review, H1 2017, provides an overview of the Blepharitis (Ophthalmology) pipeline landscape. Blepharitis is an inflammation of the eyelids, usually caused by an excess growth of bacteria that is ordinarily found on the skin, blockage of the eyelid's oil glands, and occasionally allergies. Blepharitis s......
  • Juvenile Macular Degeneration (Stargardt Disease) - Pipeline Review, H1 2017
    Published: 31-Mar-2017        Price: US 2000 Onwards        Pages: 69
    Juvenile Macular Degeneration (Stargardt Disease) - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Juvenile Macular Degeneration - Pipeline Review, H1 2017, provides an overview of the Juvenile Macular Degeneration (Ophthalmology) pipeline landscape. Juvenile macular degeneration is a series of inherited eye disorders that affects children and young adults. The most common form of juv......
  • Optic Neuropathy - Pipeline Review, H1 2017
    Published: 31-Mar-2017        Price: US 2000 Onwards        Pages: 48
    Optic Neuropathy - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Optic Neuropathy - Pipeline Review, H1 2017, provides an overview of the Optic Neuropathy (Ophthalmology) pipeline landscape. Optic neuropathy is an inherited form of vision loss. Symptoms include eye pain or discomfort, numbness, tingling and clouding of vision. Predisposing factors include age, tobacco smoke, alcohol,......
  • Proliferative Vitreoretinopathy (PVR) - Pipeline Review, H1 2017
    Published: 31-Mar-2017        Price: US 2000 Onwards        Pages: 34
    Proliferative Vitreoretinopathy (PVR) - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Proliferative Vitreoretinopathy (PVR) - Pipeline Review, H1 2017, provides an overview of the Proliferative Vitreoretinopathy (PVR) (Ophthalmology) pipeline landscape. Proliferative Vitreoretinopathy (PVR) occurs when a scar forms under or on the retina after retinal detachment, preventing the retin......
  • Global Artificial tears Sales Market Report 2017
    Published: 29-Mar-2017        Price: US 4000 Onwards        Pages: 104
    In this report, the global Artificial tears market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split global into several key Regions, with sales (Bottle), revenue (Million USD), market share and growth rate of Artificial tears for these regions, from 2012 to 2022 (forecast), covering - United States - China - Europe - Japan......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs